Knoepp Ursula W, Ravenel James G
Department of Radiology, Medical University of South Carolina, 29425, USA.
Crit Rev Oncol Hematol. 2006 Apr;58(1):15-30. doi: 10.1016/j.critrevonc.2005.09.001. Epub 2005 Dec 28.
Lung cancer is the leading cause of cancer mortality among both males and females throughout the world. Worldwide, as many as one million people are affected by the disease each year. Within the United States over 170,000 cases of lung cancer are diagnosed annually and over 150,000 lung cancer deaths will occur. Due to its prevalence, lung cancer has a great impact on health care costs annually, making it a significant public health issue. Appropriate therapy is dependent on accurate staging to determine those amenable to surgery and define the appropriate role for chemotherapy and radiation therapy. In this review, we discuss the impact of computed tomography (CT) and positron emission tomography (PET) with a primary focus on 18F-fluorodeoxyglucose (18F-FDG) on lung cancer evaluation and staging.
肺癌是全球男性和女性癌症死亡的主要原因。在全球范围内，每年多达100万人受该疾病影响。在美国，每年有超过17万例肺癌被诊断出来，并且将有超过15万例肺癌死亡病例。由于其普遍性，肺癌每年对医疗保健成本有巨大影响，使其成为一个重大的公共卫生问题。适当的治疗取决于准确的分期，以确定适合手术的患者，并确定化疗和放射治疗的适当作用。在本综述中，我们讨论计算机断层扫描（CT）和正电子发射断层扫描（PET），主要关注18F-氟脱氧葡萄糖（18F-FDG）对肺癌评估和分期的影响。
